Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
DXCM logo DXCM
Upturn stock ratingUpturn stock rating
DXCM logo

DexCom Inc (DXCM)

Upturn stock ratingUpturn stock rating
$86.33
Last Close (24-hour delay)
Profit since last BUY5.89%
upturn advisory
Consider higher Upturn Star rating
BUY since 37 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

06/27/2025: DXCM (2-star) has a low Upturn Star Rating. Not recommended to BUY.

Upturn Star Rating

ratingratingratingratingrating

Below Average Performance

These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.

Number of Analysts

rating

26 Analysts rated it

These Stocks/ETFs, based on Upturn Advisory, have historically outperformed the market, making them a top-tier choice for investors.

Year Target Price $98.45

Year Target Price $98.45

Analyst’s Price TargetsFor last 52 week
$98.45Target price
Low$57.52
Current$86.33
high$117.19

Analysis of Past Performance

Type Stock
Historic Profit 13.6%
Avg. Invested days 40
Today’s Advisory Consider higher Upturn Star rating
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 3.0
Stock Returns Performance Upturn Returns Performance 2.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 06/27/2025

Key Highlights

Company Size Large-Cap Stock
Market Capitalization 33.85B USD
Price to earnings Ratio 64.91
1Y Target Price 98.59
Price to earnings Ratio 64.91
1Y Target Price 98.59
Volume (30-day avg) -
Beta 1.46
52 Weeks Range 57.52 - 117.19
Updated Date 06/29/2025
52 Weeks Range 57.52 - 117.19
Updated Date 06/29/2025
Dividends yield (FY) -
Basic EPS (TTM) 1.33

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin 12.9%
Operating Margin (TTM) 12.91%

Management Effectiveness

Return on Assets (TTM) 5.98%
Return on Equity (TTM) 23.72%

Valuation

Trailing PE 64.91
Forward PE 43.1
Enterprise Value 33732440561
Price to Sales(TTM) 8.16
Enterprise Value 33732440561
Price to Sales(TTM) 8.16
Enterprise Value to Revenue 8.13
Enterprise Value to EBITDA 34.59
Shares Outstanding 392107008
Shares Floating 389378433
Shares Outstanding 392107008
Shares Floating 389378433
Percent Insiders 0.42
Percent Institutions 97.23

Analyst Ratings

Rating 4.54
Target Price 98.45
Buy 6
Strong Buy 17
Buy 6
Strong Buy 17
Hold 3
Sell -
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

DexCom Inc

stock logo

Company Overview

overview logo History and Background

DexCom Inc. was founded in 1999 and is headquartered in San Diego, California. The company focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for people with diabetes. DexCom has significantly advanced CGM technology, moving from sensors requiring frequent fingersticks to real-time CGM systems integrated with insulin pumps and digital health platforms.

business area logo Core Business Areas

  • Continuous Glucose Monitoring (CGM) Systems: DexCom's core business is the development and sales of CGM systems, including sensors, transmitters, and receivers (or compatible smart devices). These systems provide real-time glucose data to users, helping them manage their diabetes more effectively.

leadership logo Leadership and Structure

DexCom's leadership team consists of experienced executives in the medical device and technology industries. The company is structured around research and development, manufacturing, sales and marketing, and regulatory affairs, with a focus on innovation and market expansion.

Top Products and Market Share

overview logo Key Offerings

  • Dexcom G7: Dexcom G7 is the latest generation CGM system that provides real-time glucose readings every five minutes. This system is designed for ease of use with a simple application and integration with other devices such as insulin pumps and smartphones. Competitors include Abbott's FreeStyle Libre 3 and Medtronic Guardian Connect.
  • Dexcom G6: Dexcom G6 is a previous generation CGM system widely used for diabetes management. Market share and revenue data are not publicly segmented per product; however, G6 and G7 combined dominate the CGM market. Main competitors include Abbott's FreeStyle Libre 2 and Medtronic's Guardian Sensor 3.

Market Dynamics

industry overview logo Industry Overview

The diabetes care market, particularly the CGM segment, is experiencing rapid growth due to increasing diabetes prevalence, technological advancements, and a shift towards preventative care. The industry is competitive, with key players vying for market share through product innovation and partnerships.

Positioning

DexCom is a leading innovator and manufacturer of CGM systems. Its competitive advantages lie in its advanced technology, strong brand reputation, and established relationships with healthcare providers and payers.

Total Addressable Market (TAM)

The global diabetes care devices market is projected to reach hundreds of billions of USD by 2030. DexCom is well-positioned to capture a significant portion of this TAM through continued innovation and market expansion.

Upturn SWOT Analysis

Strengths

  • Technological innovation
  • Strong brand reputation
  • Established distribution network
  • High customer loyalty
  • Integration with insulin pumps and digital health platforms

Weaknesses

  • High product cost
  • Reliance on reimbursement policies
  • Competition from established medical device companies
  • Sensor accuracy issues reported by some users.

Opportunities

  • Expanding into new geographic markets
  • Developing next-generation CGM systems
  • Partnering with telehealth providers
  • Integrating CGM data with AI-powered diabetes management tools.
  • Expanding into non-insulin using diabetics

Threats

  • Intense competition
  • Technological obsolescence
  • Regulatory changes
  • Economic downturns
  • Reimbursement cuts from payers.

Competitors and Market Share

competitor logo Key Competitors

  • ABT
  • MDT

Competitive Landscape

DexCom competes with Abbott (ABT) and Medtronic (MDT) in the CGM market. DexCom holds advantages through technological innovation and established market presence, but faces competition from Abbott's lower-cost FreeStyle Libre system.

Growth Trajectory and Initiatives

Historical Growth: DexCom has demonstrated strong historical revenue growth driven by increasing CGM adoption and market expansion.

Future Projections: Analyst estimates project continued revenue growth for DexCom driven by product innovation, market penetration, and geographic expansion.

Recent Initiatives: Recent initiatives include the launch of Dexcom G7, partnerships with insulin pump manufacturers, and expansion into new markets.

Summary

DexCom is a strong player in the CGM market, driven by technological innovation and a robust product portfolio. Its G7 system is promising. However, it should be aware of competition from Abbot and Medtronic, as well as the potential for reimbursement cuts.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company Filings (SEC)
  • Industry Reports
  • Analyst Estimates

Disclaimers:

The information provided is for informational purposes only and should not be considered financial advice. Market share percentages are estimates and may vary.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About DexCom Inc

Exchange NASDAQ
Headquaters San Diego, CA, United States
IPO Launch date 2005-04-14
Executive Chairman & CEO Mr. Kevin Ronald Sayer
Sector Healthcare
Industry Medical Devices
Full time employees 10200
Full time employees 10200

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for the management of diabetes and metabolic health by patients, caregivers, and clinicians. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Stelo, a new over-the-counter glucose biosensor designed for adults with prediabetes and Type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.